| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:46 | TrumpRx launches to slash drug prices for cash-paying US patients | ||
| 12:46 | FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint | ||
| 12:46 | £1bn London Cancer Hub extension gets go-ahead amid UK life sciences push | ||
| 12:46 | BMS reports flat revenue growth for full-year 2025 | ||
| 11:46 | Apotex and Grünenthal sign deal for Nebido Canadian distribution | ||
| Do | Rare paediatric disease voucher programme makes long-awaited US return | ||
| Do | Eisai signs $388m deal for Japanese rights to Henlius' anti-PD-1 mAb | ||
| Do | Everest Medicines and Micot partner on MT1013 commercialisation | ||
| Do | PrimeGen US and DT Cloud Star sign $1.5bn merger agreement | ||
| Mi | GSK oncology and HIV drugs leads to 7% sales rise in 2025 | ||
| Mi | Eli Lilly soars past expectations to hit 45% sales growth in 2025 | ||
| Mi | Novo Nordisk shares tumble 18% after 2026 sales dip warning | ||
| Mi | Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer | ||
| Mi | CEPI and Samsung Biologics partner to boost global vaccine preparedness | ||
| Di | Pfizer sets sights on R&D strategy amid modest FY25 results | ||
| Di | MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 | ||
| Di | SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal | ||
| Di | Aquestive receives FDA CRL for Anaphylm allergic reaction treatment | ||
| Mo | Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site | ||
| Mo | Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data | ||
| Mo | CHMP grants positive opinion for J&J's Akeega use | ||
| Mo | CIRM unveils RAPID funding programme for rare diseases | ||
| 30.01. | FDA's new scheme to boost US manufacturing commences despite uncertainty | ||
| 30.01. | Sanofi touts strong new launch sales amid looming Dupixent patent expiry | ||
| 30.01. | AstraZeneca signs $18.5bn weight loss drug deal with CSPC |